Sanofi (SNY) stock is in focus as the company agrees to acquire Dynavax Technologies (DVAX) and the FDA rejects its multiple ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...

Cirtuvivint is a selective pan-CLK, pan-DYRK inhibitor that modulates alternative RNA splicing, including transcripts involved in oncogenic pathways. Preclinical studies have shown that CLK/DYRK ...

Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

After months of rigorous testing and analysis throughout 2025-2026, we are excited to present the most comprehensive review of over-the-counter appetite suppressant supplements specifically formulated ...

Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.